Are you invested in CEL-SCI Corporation (CVM)?
What’s up with CEL-SCI Corporation?
CEL-SCI Corporation (CVM) opened at $17.77, which means the stock is down 3.55% from yesterday’s closing price of 16.36. Today, the company has a high of $18.00 and a low of $14.81. The company has a market cap of $588.75 million with a 52-week high of $18.00 and a 52-week low of $3.70.
What about the future forCEL-SCI Corporation
The high forecast for CEL-SCI Corporation is 19.00 while the low is 6.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. CEL-SCI Corporation has a weak forecast. A weak forecast is due to the company posting consistent losses in their earning reports. The future outlook does not seem too bright as this could potentially cause the company to file for bankruptcy.. Based on this information CVM seems to be a risky buy.
About CEL-SCI Corporation
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.